CA3062291A1 - Immunotherapeutic tumor treatment method - Google Patents

Immunotherapeutic tumor treatment method Download PDF

Info

Publication number
CA3062291A1
CA3062291A1 CA3062291A CA3062291A CA3062291A1 CA 3062291 A1 CA3062291 A1 CA 3062291A1 CA 3062291 A CA3062291 A CA 3062291A CA 3062291 A CA3062291 A CA 3062291A CA 3062291 A1 CA3062291 A1 CA 3062291A1
Authority
CA
Canada
Prior art keywords
agonist
cancer
biased
tlr
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3062291A
Other languages
English (en)
French (fr)
Inventor
Saul KIVIMAE
Marlene HENNESSY
Neel K. Anand
Haiying CAI
Bo-Liang Deng
Zhongxu Ren
Bhalchandra V. Joshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CA3062291A1 publication Critical patent/CA3062291A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3062291A 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method Pending CA3062291A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762500486P 2017-05-02 2017-05-02
US62/500,486 2017-05-02
US201762502051P 2017-05-05 2017-05-05
US62/502,051 2017-05-05
PCT/US2018/030714 WO2018204528A1 (en) 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method

Publications (1)

Publication Number Publication Date
CA3062291A1 true CA3062291A1 (en) 2018-11-08

Family

ID=64016803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062291A Pending CA3062291A1 (en) 2017-05-02 2018-05-02 Immunotherapeutic tumor treatment method

Country Status (11)

Country Link
US (1) US12054553B2 (enExample)
EP (1) EP3628010A4 (enExample)
JP (1) JP7165680B2 (enExample)
KR (1) KR102785429B1 (enExample)
CN (1) CN110582300B (enExample)
AU (1) AU2018261102B2 (enExample)
CA (1) CA3062291A1 (enExample)
IL (1) IL270329B2 (enExample)
MA (1) MA48862A (enExample)
MX (1) MX2019013071A (enExample)
WO (1) WO2018204528A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018261102B2 (en) 2017-05-02 2025-01-23 Nektar Therapeutics Immunotherapeutic tumor treatment method
EP3794022A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス, インコーポレイテッド 活性化可能なインターロイキン-2ポリペプチド及びその使用方法
BR112021011592A2 (pt) * 2019-01-04 2021-10-26 Ascendis Pharma Oncology Division A/S Conjugados de agonistas de receptor de reconhecimento de padrão
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. Water soluble adjuvant and composition containing same
JP7754723B2 (ja) 2019-05-14 2025-10-15 ウェアウルフ セラピューティクス, インコーポレイテッド 分離部分及びその使用方法
US20220370563A1 (en) * 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE10248141B4 (de) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US20050079155A1 (en) 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP2279758B1 (en) 2005-06-16 2015-02-25 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CN103153338A (zh) * 2010-05-07 2013-06-12 贝勒研究院 树突细胞免疫受体(dcir)介导的人类cd8+t细胞的交叉敏化
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Il-2 부분 및 중합체의 접합체
WO2012088422A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CA2826582A1 (en) * 2011-02-10 2012-08-16 University Of Louisville Research Foundation, Inc. Adjuvant compositions with 4-1bbl
HRP20210377T1 (hr) 2014-02-21 2021-04-16 Nektar Therapeutics Il-2rbeta-selektivni agonisti u kombinaciji s anti-ctla-4 protutijelom ili anti-pd-1 protutijelom
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
AU2018207283C1 (en) * 2017-01-10 2024-05-02 Nektar Therapeutics Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
AU2018261102B2 (en) 2017-05-02 2025-01-23 Nektar Therapeutics Immunotherapeutic tumor treatment method
EP3668548A2 (en) * 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method

Also Published As

Publication number Publication date
KR20190141760A (ko) 2019-12-24
MA48862A (fr) 2020-04-01
JP2020518610A (ja) 2020-06-25
IL270329B1 (en) 2025-08-01
IL270329B2 (en) 2025-12-01
JP7165680B2 (ja) 2022-11-04
CN110582300B (zh) 2024-08-02
EP3628010A4 (en) 2021-02-17
WO2018204528A1 (en) 2018-11-08
MX2019013071A (es) 2019-12-11
AU2018261102B2 (en) 2025-01-23
US20210292425A1 (en) 2021-09-23
CN110582300A (zh) 2019-12-17
IL270329A (enExample) 2019-12-31
KR102785429B1 (ko) 2025-03-21
AU2018261102A1 (en) 2019-11-07
US12054553B2 (en) 2024-08-06
EP3628010A1 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
US12214045B2 (en) Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US12030940B2 (en) Immunotherapeutic tumor treatment method
US12054553B2 (en) Immunotherapeutic tumor treatment method
US20250090658A1 (en) Polymer adjuvant
Lynn et al. Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and mechanism of CD8 T cell induction
KR20110052648A (ko) 다분지형 중합체 알카노에이트 컨쥬게이트
CA3195623A1 (en) Star polymer drug conjugates
JP7471600B2 (ja) 抗原ペプチド-アジュバントヌクレオチドコンジュゲート体を含む免疫誘導剤及びそれを含む医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230427

EEER Examination request

Effective date: 20230427

EEER Examination request

Effective date: 20230427